Home » Case Studies » Value Access and Pricing » Launch Strategy Alignment Work…

Launch Strategy Alignment Workshop

CBPartners organized a full day on-site workshop to bring together key cross functional client teams to align on a final PRODUCT X launch strategy in mNSCLC in Japan.


Build alignment on the launch pricing & market access assumptions for PRODUCT X in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks.



Conduct targeted secondary research to determine the existing mNSCLC and mCRC treatment paradigm, as well as oncology regulatory landscape in Japan. Organize a full-day day workshop at the client’s local office in Japan to enable cross functional client teams to collaborate on forecasting assumptions and optimal launch strategies.


  • Case studies of oncology analogues and recent pricing outcomes in JPN
  • In-depth policy review of JPN’s new health technology assessment (HTA) process
  • Final report with detailed summary of workshop outputs
  • Final launch pricing and commercial strategy

Illustrative Outputs


Workshop output enabled the client to identify likely PRODUCT X HTA outcomes in JPN and update their launch forecast model to include realistic access assumptions.